...Okay. Great. Welcome, everyone. I'm Yigal Nochomovitz. I'm one of the biotech analysts here at Citi. Welcome to the panel on Autologous, Allogeneic CAR-T, CAR-NK & More - Exploring the State of Play in Cell Therapy. And it's my great pleasure to have with me today from Atara Bio, Pascal Touchon, who's the President and CEO; from Caribou Biosciences that recently went public, Rachel Haurwitz, President and CEO; from Cellectis, Andre Choulika, the CEO; and from Gracell Bio, William Cao, the Chairman and CEO. So welcome all of you today. Thank you very much for taking the time....